ArticleOphthalmology and therapy2019
A Pilot Study on the Efficacy and Safety of 0.01% Atropine in German Schoolchildren with Progressive Myopia.
Article in Ophthalmology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Cost of Myopia Correction: A Systematic Review.Frontiers in medicine · 2021Pooled it
- Changes in accommodation and vergence parameters with topical use of 0.025% and 0.05% atropine in myopes aged between 7 and 17 years.Eye (London, England) · 2025Trial
- Effect of Repeated Low-Level Red Light Versus 0.01% Topical Atropine on Myopia Progression: A Randomized Crossover-Controlled Trial.Translational vision science & technology · 2025Trial
- Effect of atropine 0.01% on progression of myopia.Indian journal of ophthalmology · 2022Trial
- Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial.Scientific reports · 2021Trial
- A multicenter Spanish study of atropine 0.01% in childhood myopia progression.Scientific reports · 2021Trial
- Management of myopia: a mini-review.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- The Effect of Repeated Low-Level Red Light Versus 0.01% Atropine Treatment on Axial Length and Choroidal Parameters in Children with Myopia.Ophthalmology and therapy · 2025Article
- Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye.Turkish journal of ophthalmology · 2025Article
- Myopi-X lenses vs. low-dose atropine in myopia control: a Turkish retrospective study : Study design: retrospective observational study.BMC ophthalmology · 2025Observational
- Context of Atropine Adherence in Preschool Children with Early-Onset Myopia: A Qualitative Study.Children (Basel, Switzerland) · 2024Article
- The Effect of Alternating Monocular Instillation of 0.125% Atropine in Korean Children with Progressive Myopia.Journal of clinical medicine · 2024Article
- Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners.Eye (London, England) · 2024Review
- Article
- [Recommendations for progressive myopia in childhood and adolescence. Statement of the DOG, BVA and the Bielschowsky Society for Strabismus Research and Neuroophthalmology : Status June 2022].Die Ophthalmologie · 2023Review
- Deep learning system to predict the 5-year risk of high myopia using fundus imaging in children.NPJ digital medicine · 2023Article
- Current concepts in the management of childhood myopia.Indian journal of ophthalmology · 2022Review
- Characteristics of responders to atropine 0.01% as treatment in Asian myopic children.Scientific reports · 2022Observational
- The Role of Atropine in Preventing Myopia Progression: An Update.Pharmaceutics · 2022Review
- Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children.Ophthalmology and therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough the interest is growing in topical low-dose atropine to control myopia in schoolchildren worldwide, its use in children of European ancestry remains controversial and solid evidence is sparse. The Oxford Centre for Evidence Based Medicine (OCEBM) classifies the evidence for this therapy as level I for East Asian populations, but only level IV in non-Asian populations.
methodsFifty-six children, aged a median of 11 years (range 6-17), were analysed after 12 months of topical treatment with 0.01% preservative-free atropine in both eyes at bedtime every day. Efficacy was assessed during treatment every 6 months. In a subset of 20 patients, treatment of the second eye was delayed by 1 day to enable a controlled safety assessment of side effects such as pupil dilation, hypoaccommodation, and near vision reduction.
resultsPrior to treatment, the mean myopic progression was estimated as 1.05 D/year; after 12 months of treatment with 0.01% atropine, it was 0.40 D/year (p < 0.0001). The only consistently measurable side effect was the induction of 1 mm pupil dilatation, which was only noticeable in comparison to the non-treated eye during the safety investigation.
conclusionsTopical low-dose atropine appears to be safe and efficacious also in a cohort of European schoolchildren. These data should motivate researchers to conduct more randomised clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.